Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

By sjmartinez • October 28, 2022

Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. Oncologist. 2022 Oct 27:oyac219. doi: 10.1093/oncolo/oyac219. Epub ahead of print. PMID: 36302223.

Tags: administrative claims, Dermatology, healthcare, Healthcare cost, immune checkpoint inhibitors, melanoma, molecular targeted therapy, Publications

Corrigendum: Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response

Santos P, Rezende CP, Piraine R, Oliveira B, Ferreira FB, Carvalho VS, Calado RT, Pellegrini M, Almeida F. Corrigendum: Extracellular vesicles from human breast cancer-resistant[...]

Stepwise neofunctionalization of the NF-κB family member Rel during vertebrate evolution

Daly AE, Chang AB, Purbey PK, Williams KJ, Li S, Redelings BD, Yeh G, Wu Y, Pope SD, Venkatesh B, Li S, Nguyen K, Rodrigues[...]

Emergency vs. Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Healthcare Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency vs. Outpatient Care for Pediatric Atopic[...]